# Dysferlin stabilizes membrane nanodomains of cardiomyocytes after myocardial infarction

**Authors:** Justus B. Wegener, Yannik Zühlke, Carolin Fleischhacker, Justus Marks, Brian Foo, Niklas Bader, Gabriel C. Riedemann, Jasper Wedemeyer, Kim-Chi Vu, Ana M. Vergel Leon, Nora Josefine Paulke, Tobias Kohl, Henning Urlaub, Constanze Schmidt, Gerd Hasenfuß, Tobias Moser, Eva A. Rog-Zielinska, Christof Lenz, Stephan E. Lehnart, Sören Brandenburg

PMC · DOI: 10.1038/s41598-026-42800-9 · 2026-03-26

## TL;DR

This study shows that the protein dysferlin helps protect heart cells after a heart attack by stabilizing key membrane structures, which may reduce heart function loss.

## Contribution

The study identifies dysferlin as a novel molecular target for preserving sarcolemmal nanodomains in the heart after myocardial infarction.

## Key findings

- Dysferlin expression increases by 230% in the MI border zone of wild-type mice.
- Dysferlin-knockout mice show larger infarct sizes and reduced heart function after MI.
- Dysferlin stabilizes TAT and ICD nanodomains, as shown by proteomic and imaging analyses.

## Abstract

Despite advances in acute care medicine, myocardial infarction (MI) remains a predominant cause of premature death and heart failure. In the MI border zone, cardiomyocytes are exposed to high biomechanical stress that impairs the integrity of the sarcolemmal membrane. Hence, we hypothesized that the Ca2+-sensitive membrane repair protein dysferlin is crucial for preserving sarcolemmal nanodomains in the MI border zone, like the transverse-axial tubule (TAT) network and the intercalated disc (ICD) membrane folds, and thereby limits the post-MI loss of myocardial function. We employed left anterior descending artery ligation to induce MI in wild-type (WT) versus dysferlin-knockout (KO) mice. While immunohistology identified an upregulated dysferlin expression of 230% in cardiomyocytes of the WT MI border zone, KO mice presented larger infarct sizes and reduced left-ventricular systolic function one week post-MI. To dissect the role of dysferlin in left-ventricular remodelling post-MI, we applied data-independent acquisition mass-spectrometry (DIA-MS) analysing the spatial proteomic profiles in WT versus KO hearts. In total, DIA-MS quantitated 5,700 proteins across all small samples, thereby identifying hundreds of genotype-specific proteomic changes for the left-ventricular infarct, border and remote zones one week post-MI. Complementing with our proteomic results, confocal and super-resolution stimulated emission depletion (STED) microscopy visualized severely degraded TAT membranes and enlarged ICD membrane folds in cardiomyocytes of the MI border zone. Importantly, extensive dysferlin signals clustered in vicinity to residual TAT structures and connexin-43 plaques at the ICD, indicating a stabilizing role of dysferlin in sarcolemmal nanodomain organization. In fact, co-immunoprecipitation-based DIA-MS and complexome profiling decoding the functional cardiac interactome of dysferlin confirmed prominent dysferlin interaction partners at TAT and ICD nanodomains. In conclusion, dysferlin represents a new molecular target that protects the integrity of sarcolemmal nanodomains in cardiomyocytes of the MI border zone, thereby reducing loss of contractility post-MI.

The online version contains supplementary material available at 10.1038/s41598-026-42800-9.

## Linked entities

- **Genes:** FER1L5 (fer-1 like family member 5) [NCBI Gene 102083753], CONNEXIN 43 (CONNEXIN 43 protein) [NCBI Gene 443455]
- **Proteins:** FER1L5 (fer-1 like family member 5), CONNEXIN 43 (CONNEXIN 43 protein)
- **Diseases:** myocardial infarction (MONDO:0005068), heart failure (MONDO:0005252)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Jph2 (junctophilin 2) [NCBI Gene 59091] {aka 1110002E14Rik, JP-2, Jp2}, TRIM72 (tripartite motif containing 72) [NCBI Gene 493829] {aka MG53}, Aqp1 (aquaporin 1) [NCBI Gene 11826] {aka CHIP28}, CAV3 (caveolin 3) [NCBI Gene 859] {aka LGMD1C, LQT9, MPDT, RMD2, VIP-21, VIP21}, ANK3 (ankyrin 3) [NCBI Gene 288] {aka ANKYRIN-G, MRT37}, Tat (tyrosine aminotransferase) [NCBI Gene 234724], GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, Dysf (dysferlin) [NCBI Gene 26903] {aka 2310004N10Rik, D6Pas3}, DYSF (dysferlin) [NCBI Gene 8291] {aka FER1L1, LGMD2B, LGMDR2, MMD1}, Trim72 (tripartite motif-containing 72) [NCBI Gene 434246] {aka MG53}, TMEM65 (transmembrane protein 65) [NCBI Gene 157378], Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, TAT (tyrosine aminotransferase) [NCBI Gene 6898], GNPTAB (N-acetylglucosamine-1-phosphate transferase subunits alpha and beta) [NCBI Gene 79158] {aka GNPTA, ICD}, NEAT1 (nuclear paraspeckle assembly transcript 1) [NCBI Gene 283131] {aka LINC00084, NCRNA00084, TP53LC15, TncRNA, VINC}, Cdh2 (cadherin 2) [NCBI Gene 12558] {aka CDHN, N-CAD, Ncad}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, Ryr2 (ryanodine receptor 2, cardiac) [NCBI Gene 20191] {aka 9330127I20Rik, RYR-2}, JPH2 (junctophilin 2) [NCBI Gene 57158] {aka CMD2E, CMH17, JP-2, JP2}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, Anxa11os (annexin A11, opposite strand) [NCBI Gene 105245705] {aka Gm9872}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, Gja3 (gap junction protein, alpha 3) [NCBI Gene 14611] {aka Cnx46, Cx43, Cx46, Cxnj1, Gja-3}, CHD2 (chromodomain helicase DNA binding protein 2) [NCBI Gene 1106] {aka DEE94, EEOC}, Gja1 (gap junction protein, alpha 1) [NCBI Gene 14609] {aka Cnx43, Cx43, Cx43alpha1, Cxnk1, Gja-1, Npm1}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, KCNJ11 (potassium inwardly rectifying channel subfamily J member 11) [NCBI Gene 3767] {aka BIR, HHF2, IKATP, KIR6.2, MODY13, PHHI}, Tfrc (transferrin receptor) [NCBI Gene 22042] {aka 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1}, Cav3 (caveolin 3) [NCBI Gene 12391] {aka Cav-3, M-cav}, Gh (growth hormone) [NCBI Gene 14599] {aka Gh1, Ghb1}
- **Diseases:** LV hypertrophy (MESH:D017379), dislocation (MESH:D004204), R (MESH:C580424), ischemic (MESH:D002545), -MI (MESH:D009203), premature death (MESH:D003643), Infarct (MESH:D007238), loss of ventricular function (MESH:D014693), hypoxia (MESH:D000860), skeletal muscle disease (MESH:D005207), CF (MESH:D003550), dilated cardiomyopathy (MESH:D002311), LGMD R2 (MESH:D049288), Heart failure (MESH:D006333), Sarcoplasmic reticulum (MESH:D008228), cardiomyocyte hypertrophy (MESH:D006984), inflammation (MESH:D007249), LV remodelling (MESH:D020257), I/R) injury (MESH:D015427), LV dilation (MESH:C565277), Myocardial ischemia (MESH:D017202), CM (MESH:D009202), Ischemia (MESH:D007511)
- **Chemicals:** Ca2+ (-), paraffin (MESH:D010232), isoflurane (MESH:D007530), HC (MESH:D006854), CHAPS (MESH:C028213), DIA (MESH:C076868), oil (MESH:D009821), acetone (MESH:D000096), Triton-X100 (MESH:D017830), fentanyl (MESH:D005283), amine (MESH:D000588), SDS (MESH:D012967), sodium citrate (MESH:D000077559), midazolam (MESH:D008874), HCl (MESH:D006851), nitrogen (MESH:D009584), NaCl (MESH:D012965), HEPES (MESH:D006531), uranyl acetate (MESH:C005460), copper (MESH:D003300), medetomidine (MESH:D020926)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C through E, D through E, G through H, F through H, I through L, A through C, D through I, F through G
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13031966/full.md

---
Source: https://tomesphere.com/paper/PMC13031966